Key Points Walgreens is an iconic brand in the pharmacy space, but it has fallen on hard times.The retailer has agreed to be ...

Shareholders for Walgreens Boots Alliance overwhelmingly voted to approve the company’s sale to Sycamore Partners, with 96% of shareholders at a special meeting voting to green-light the merger, ...

Walgreens Boots Alliance is going private at $11.45/share plus up to $3 via a CVR, offering a potential $14.45 payout. See ...

Walgreens Boots Alliance shareholders approved the company’s sale to private equity firm Sycamore Partners at a July 11 special meeting. Walgreens announced in March that it had entered into a ...

By overwhelmingly approving the $10 billion sale to private-equity firm Sycamore Partners, investors set an official end date on Walgreens’ run as one of Chicago’s most iconic public companies ...

Walgreens Boots Alliance reported adjusted earnings per share of 38 cents for the third quarter of its 2025 fiscal year, which beat Zacks Investment Research's estimate of 34 cents per share.

Walgreens Boots Alliance shareholders have approved the company’s $10 billion acquisition by private equity firm Sycamore Partners during a special meeting held July 11. Here are four more notes to ...

Walgreens and Sycamore expect to close the take-private deal in the fourth quarter of this year. Shares of Walgreens jumped more than 5% in after-hours trading on Thursday before being halted.

Retail Gazette takes a closer look at Boots' new private equity owner and what the deal means for the future of the health ...

The shareholders of Boots' parent company have approved the US group's sale to private equity firm Sycamore Partners, leaving the future unclear for the UK pharmacy giant.

Walgreens Boots Alliance, Inc. (NASDAQ:WBA) announced a definitive agreement to be acquired by Sycamore Partners in March in a transaction valued at up to $23.7 billion.

Walgreens swings to a loss ahead of Sycamore acquisition Store closures and weak front-of-store comps led to a retail sales decline in Q3, but U.S. pharmacy and international sales were strong.